Skip to content

Characterization of Influenza-like Illness in Mexico

An Observational Study to Characterize Children and Adults With Influenza Like Illness (ILI) in Mexico

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01418287
Enrollment
5819
Registered
2011-08-17
Start date
2010-04-30
Completion date
2014-05-31
Last updated
2014-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza-like Illness

Brief summary

A study to characterize children and adults with influenza like symptoms and to determine risk factors for severe disease and death among those with H1N1.

Detailed description

In March 2009, a new influenza A virus, novel H1N1 (commonly referred to as swine flu), began causing an increase in reports of influenza-like illness in North America. Although the virus subsequently spread rapidly around the world, the earliest reported outbreak of cases occurred in Mexico City, which is seen as the epicenter of the influenza pandemic, the world's first in 40 years. Many questions remain about this emerging pandemic and the virus causing it, the answers to which could better inform patient management and policy decisions both in Mexico and internationally. Sparse reliable clinical research data have been collected on the natural history of the disease, on the risk factors associated with severe disease, or on the severity of this pandemic influenza as compared to seasonal influenzas. This study is an initial step to better characterize individuals in Mexico who develop influenza-like illness (including illness caused by novel H1N1), to describe the clinical management of those individuals, and to assess their short-term outcome. The planned data collection will provide timely information to inform policy and guidelines for the local populations and governments involved and may also be used to design future ancillary studies of this influenza virus and/or studies of other emerging infectious diseases. The purpose of this observational study is to characterize individuals in Mexico who seek medical care for influenza-like illness (ILI) and to describe clinical course over a period of at least 28 days after enrollment.

Interventions

None listed

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
CollaboratorNIH
Secretaria de Salud, Mexico
CollaboratorOTHER_GOV
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
CollaboratorOTHER
Instituto Nacional de Enfermedades Respiratorias
CollaboratorOTHER_GOV
National Institute of Pediatrics, Mexico
CollaboratorOTHER_GOV
Hospital General Dr. Manuel Gea González
CollaboratorOTHER_GOV
Hospital Infantil de Mexico Federico Gomez
CollaboratorOTHER
Hospital Central Dr. Ignacio Morones Prieto
CollaboratorOTHER
Mexican Emerging Infectious Diseases Clinical Research Network
Lead SponsorNETWORK

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Signed informed consent by participant, or for pediatric participants, signed informed consent by parent/legal guardian and, where appropriate, signed assent by participant * At least one respiratory symptom (e.g., shortness of breath, postnasal drip, cough) and * One of the following criteria: * Fever (≥ 38 °C by any method: oral, axillary, etc.) on examination or participant-reported fever (≥ 38° C) or feverishness in the past 24 hours * One or more non-respiratory symptoms (e.g., malaise, headache, myalgia,chest pain) * Consenting to provide aspirate or naso-pharyngeal swab

Exclusion criteria

* The onset of illness is more than 48 hours after hospitalization. * Participants previously included in this study within the last 30 days.

Design outcomes

Primary

MeasureTime frameDescription
Characterize individuals who develop influenza-like illness, influenza A, and/or H1N1 or other viruses5 yearsCharacterize demographics, co-morbid conditions, prior influenza vaccination, the use of antivirals, and clinical course and treatment

Secondary

MeasureTime frameDescription
Death5 yearsFor all participants, to estimate the percentage who die
Hospitalization5 yearsFor all participants, to estimate the percentages who require hospitalization due to severe influenza
Risk factors5 yearsFor all participants, to determine risk factors for severe disease
Repository of oropharyngeal and nasal samples5 yearsEstablish a repository of oropharyngeal and nasal samples to determine a precise diagnosis, to molecularly characterize the virus
Repository of serum and PBMC5 yearsEstablish a repository of serum and PBMC to study biomarkers that predispose and correlate with severe influenza

Countries

Mexico

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 12, 2026